Stockreport

Sub-Group Analysis of Novocure’s EF-14 Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Published in Journal of Neuro-Oncology Demonstrating More Time on Optune® Predicted Increased S...

NovoCure Limited - Ordinary Shares  (NVCR) 
Last novocure limited - ordinary shares earnings: 4/30 06:00 am Check Earnings Report
US:NASDAQ Investor Relations: novocure.com/investor-relations
PDF Patients who used Optune more than 90 percent of the time experienced a median overall survival of 24.9 months Monthly usage was a predictor of s [Read more]